Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Grupo Supervielle Q4 2025 Earnings Call - Loan Growth Outpaced Stress as Provisions Peaked and CET1 Rose to 15.4%
Q4 2025 was a transition quarter for Grupo Supervielle, marked by aggressive loan growth, a peak in provisioning and an improving margin backdrop. Loans rose 8% sequentially and 37% year over year, dr...
- Total loans grew 8% sequentially and 37% year over year, with corporate lending rising 25% q/q and now representing 63% of the portfolio.
- Retail balances declined 4% q/q and grew only 8% y/y, reflecting deliberate tightening of underwriting to prioritize risk adjusted returns.
- NPL ratio increased to 5.0% from 3.9% in the prior quarter, consistent with system wide stress and prior rapid loan growth.
- +12 more takeaways
Limbach Holdings Q4 and FY 2025 Earnings Call - ODR-Led Revenue Surge, Pioneer Margin Wildcard
Limbach closed 2025 with a clear regime change, driven by owner direct repair and replacement work. Revenue jumped 24.7% to $646.8 million, adjusted EBITDA hit a record $81.8 million, free cash flow w...
- Total 2025 revenue rose 24.7% to $646.8 million, the first substantial revenue growth since 2020 as the company executes its strategic shift to ODR.
- ODR now dominates the business, representing about 75% of full year revenue and 77.6% of Q4 revenue, with total ODR revenue up 40.6% year over year.
- Organic ODR growth was a robust 17% for the year; management is guiding 9% to 12% organic ODR growth for 2026.
- +12 more takeaways
Helios Technologies Q4 FY2025 Earnings Call - Return to Growth, Record Cash, But Cautious Roadmap Amid Tariffs and Chip Risk
Helios closed fiscal 2025 with a clear turnaround: back-to-back quarters of profitable sales growth, stronger margins and record cash generation. Q4 revenue beat expectations and the company finished ...
- Q4 revenue $211.0 million, up 17% year-over-year; on a pro forma basis excluding the CFP divestiture, Q4 sales rose 29% year-over-year.
- Full year sales $839.0 million, up 4% reported; on a pro forma basis (ex-CFP) full year revenue rose about 6% — first year of top-line growth after multi-year declines.
- Gross margin expanded to 33.6% in Q4, a 350 basis point improvement year-over-year, driven by higher volumes, mix and productivity gains.
- +12 more takeaways
Tidewater Inc. Q4 and Full Year 2025 Earnings Call - $500M Wilson’s Acquisition Signals Aggressive Capital Deployment Backed by Strong Free Cash Flow
Tidewater closed 2025 with a tidy but meaningful beat: revenue of $1.35 billion, EBITDA of about $598 million, and free cash flow of roughly $426 million, capped by a $151 million free cash flow quart...
- Tidewater reported full year 2025 revenue of $1.35 billion and adjusted EBITDA of $598.1 million, with gross margin about 49.2% for the year.
- Free cash flow was robust at $426 million for 2025, with Q4 free cash flow of $151.2 million driven largely by working capital improvements and Pemex cash collections.
- Management completed a strategic vessel ownership realignment in Q4 that generated a one-time non-cash tax benefit of $201.5 million, which materially boosted reported net income for the year.
- +12 more takeaways
L.B. Foster Q4 2025 Earnings Call - Strong Q4 finish lifts results, rail backlog recovery underpins 2026 optimism
L.B. Foster closed 2025 with a rescue-quarter performance, driven by a blistering fourth quarter that pushed full-year sales to $540 million and adjusted EBITDA to $39.1 million. Q4 sales jumped 25.1%...
- Q4 2025 net sales were $160.4 million, up 25.1% year over year, the company’s strongest fourth quarter since 2018.
- Adjusted EBITDA for Q4 was $13.7 million, up 89% versus prior year, driven by higher volumes and a 470 basis point improvement in SG&A as a percent of sales.
- Full-year 2025 sales totaled $540 million, up 1.7% YoY, with adjusted EBITDA for the year of $39.1 million, up $5.5 million versus 2024.
- +13 more takeaways
EVgo Q4 2025 Earnings Call - Achieved Adjusted EBITDA Breakeven; pivoting to aggressive 2026 scale-up
EVgo closed 2025 by hitting the milestone management set when the current CEO arrived: adjusted EBITDA breakeven in the fourth quarter and for the full year. Revenue jumped to $384 million, up 50% yea...
- EVgo achieved adjusted EBITDA breakeven in Q4 2025 and for the full year, marking the company milestone set when the current CEO joined in late 2023.
- Full year 2025 revenue was $384 million, a 50% increase versus 2024, with charging network revenue of $218 million (up 40%), extend revenue of $116 million (up 34%), and ancillary revenue of $49 million (up 239% driven in part by a $26 million contract buyout).
- The network ended 2025 with 5,100 stalls in operation after adding ~1,200 stalls in 2025 and a record 500-stall deployment in Q4. EVgo now operates over 1,200 stations across 47 states.
- +13 more takeaways
908 Devices Fourth Quarter 2025 Earnings Call - Reached Q4 Positive Adjusted EBITDA as VipIR and XplorIR Drive FTIR-led Growth
908 Devices closed 2025 with clear signs the company’s turnaround is taking hold. Q4 revenue from continuing operations was $17.4 million, up 21% year over year, and management reported a positive adj...
- Q4 2025 revenue from continuing operations was $17.4 million, up 21% year over year; full year revenue was $56.2 million, up 18% versus 2024.
- 908 Devices achieved positive adjusted EBITDA in Q4 2025 of $0.7 million, a swing from a $4.0 million adjusted EBITDA loss in Q4 2024.
- Full year adjusted EBITDA loss narrowed to $9.6 million, a 39% improvement versus 2024; management expects to cut the 2025 adjusted EBITDA loss roughly in half in 2026.
- +12 more takeaways
Scholar Rock Q4 2025 Earnings Call - BLA resubmission and 2026 U.S. launch contingent on Catalent reinspection
Scholar Rock told investors it is ready to resubmit the apitegromab BLA and push for a U.S. launch in 2026, but the timing hinges squarely on a successful FDA reinspection of the Catalent Indiana fill...
- Company is prepared to resubmit the apitegromab BLA and reaffirmed guidance of BLA re‑submission and U.S. launch following approval in 2026, contingent on a successful FDA reinspection of the Catalent Indiana facility.
- FDA issued a warning letter to Catalent Indiana after the Type A meeting; Novo Nordisk submitted a remediation plan and FDA has had high-touch engagement, including sending a field team to the site.
- Following the FDA field visit, routine manufacturing at Catalent resumed in late February and FDA stated it intends to conduct a site reinspection after those activities; Scholar Rock says a successful reinspection is the gating item for resubmission.
- +12 more takeaways
On Holding AG Q4 2025 Earnings Call - Crossed CHF 3 billion as premium innovation and LightSpray scale
On reported a landmark 2025, surpassing CHF 3 billion in net sales as premium positioning, product innovation, and retail expansion all accelerated. Sales rose 36% at constant currency, gross profit m...
- On crossed the CHF 3 billion net sales threshold in 2025, reporting 36% growth at constant currency for the year.
- Full-year gross profit margin reached a record 62.8%, Q4 gross margin hit 63.9%, demonstrating strong full-price execution and mix benefits.
- Adjusted EBITDA margin for 2025 was 18.8%, above prior aspirations; 2026 guidance for adjusted EBITDA is 18.5% to 19%.
- +14 more takeaways
Great Elm Capital Corporation Q4 2025 Earnings Call - NAV Falls to $8.07 as Management De-Risks and Preserves Liquidity
Great Elm reported a painful fourth quarter, with NAV sliding from $10.01 at Sept 30, 2025 to $8.07 at Dec 31, 2025, though pro forma NAV was $8.23 after an incentive fee waiver. Management is explici...
- NAV dropped from $10.01 on Sept 30, 2025 to $8.07 on Dec 31, 2025, pro forma NAV was $8.23 after management waived incentive fees.
- Great Elm Capital Management waived all accrued and unpaid incentive fees through March 31, 2026, a benefit of approximately $2.3 million or $0.16 per share to shareholders.
- Net investment income (NII) rose to $44.4 million or $0.31 per share in Q4, up from $2.4 million or $0.20 per share in Q3, driven largely by higher cash income and stronger CLO JV distributions.
- +17 more takeaways